CIRCULATING ENDOTHELIN-1 REDUCES SPLANCHNIC AND RENAL BLOOD-FLOW AND SPLANCHNIC GLUCOSE-PRODUCTION IN HUMANS

The effect of minimal changes in circulating plasma endothelin-l (ET-1 ) was studied in 12 healthy subjects receiving either 60 min of ET-1 ( 0.2 pmol . kg(-1). min(-1)) or physiological saline intra venously. Bl ood was drawn from arterial, renal, and central hepatic vein catheters . Arterial ET-l-like immunoreactivity (ET-1-LI) increased from 4.7 +/- 0.4 (SE) to 8.6 +/- 1.0 pmol/l during ET-1 infusion. After 10 min, pl asma ET-1-LI had increased to 6.12 +/- 0.29 pmol/l. For comparison the plasma ET-I-LI level was 12.9 +/- 4.2 pmol/in five patients with seps is syndrome. Mean arterial blood pressure rose from 92 +/- 3 to 99 +/- 4 mmHg. Estimated splanchnic and renal blood flows fell by 18 +/- 5 a nd 10 +/- 3%, respectively, and splanchnic glucose production fell by 42 +/- 6% within 10 min of the ET-1 infusion and differed compared wit h corresponding control values. Only estimated splanchnic blood flow h ad increased 60 min after the ET-1 infusion. No change in splanchnic u ptake of lactate or glycerol was seen. In conclusion, we suggest that circulating ET-1 with small or no demonstrable change in plasma concen tration interferes with vasoactivity and splanchnic glycogenolyses in health and possibly pathophysiological conditions.